NCT04040816View on ClinicalTrials.gov

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

August 1, 2020

Study Completion Date

August 30, 2020

Conditions
GoutHyperuricemia
Interventions
DRUG

SAP-001

SAP-001 or placebo treatment in a 4:1 randomization ratio

Trial Locations (6)

27612

M3 Wake Research, Inc, Raleigh

33143

Miami Research Associates, South Miami

35294

University of Alabama at Birmingham, Birmingham

66212

Vince & Associates Clinical Research, Inc., Overland Park

83642

Advanced Clinical Research, Meridian

92801

Anaheim Clinical Trials (ACT), Anaheim

All Listed Sponsors
lead

Shanton Pharma Co., Ltd.

INDUSTRY

NCT04040816 - Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients | Biotech Hunter | Biotech Hunter